The gut hormones and their roles in obesity and gastric restrictive surgery

Current Opinion in Endocrinology and Diabetes

Volumn 10, Issue 5, 2003, Pages 322-329

  Adrian, Thomas E ^a   Denham, Woody ^a   Prystowsky, Jay ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Bariatric surgery; Diabetes mellitus; Hormonal peptides

Indexed keywords

LEPTIN;

BARIATRIC SURGERY; BODY MASS; DIGESTIVE SYSTEM; GASTRECTOMY; HUMAN; METABOLIC SYNDROME X; NONHUMAN; OBESITY; REVIEW; SURGICAL TECHNIQUE; WEIGHT REDUCTION;

EID: 33750294464     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-200310000-00003     Document Type: Review

References (63)

1. Fontaine KR, Redden DT, Wang C, et al.: Years of life lost due to obesity. JAMA 2003, 289:187-193. Indicates the impact of obesity on mortality with ethnic and sex differences.
2. Deitel M, Shikora S: The development of the surgical treatment of morbid obesity. J Am Coll Nutr 2002, 21:365-371. Review of the development of surgery for morbid obesity.
3. Geloneze B, Tambascia MA, Pareja JC, et al.: The insulin tolerance test in morbidly obese patients undergoing bariatric surgery. Obes Res 2001, 9:763-769.
4. Hickey MS, Pories WJ, MacDonald KG, et al.: A new paradigm for type 2 diabetes mellitus: could it be a disease of the foregut? Ann Surg 1998, 227:637-644.
5. Rubino F, Gagner M: Potential of surgery for curing type 2 diabetes mellitus. Ann Surg 2002, 236:554-559. Impact of bariatric surgery on improving type 2 diabetes mellitus.
6. Naslund E, Gryback P, Backman L, et al.: Distal small bowel hormones: correlation with fasting antroduodenal motility and gastric emptying. Dig Dis Sci 1998, 43:45-52.
7. Bobbini-Harsch E, Morel P, Huber O, et al.: Energy economy hampers body weight loss after gastric bypass. J Clin Endocrinol Metab 2000, 85:4695-4700.
8. van Gemert WG, Westerterp KR, van Acker BAC, et al.: Energy, substrate and protein metabolism in morbid obesity before, during and after massive weight loss. Int J Obes 2000, 24:711-718.
9. Eisenstein J, Greenberg A: Ghrelin: update 2003. Nutr Rev 2003, 61:101-104. An update on the biology and pathophysiology of ghrelin.
10. Faraj M, Havel PJ, Phelis S, et al.: Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 2003, 88:1594-1602. Effects of weight loss after gastric bypass on circulating levels of adiponectin, leptin, and ghrelin.
11. Cummings DE, Weigle DS, Frayo RS, et al.: Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Eng J Med 2002, 346:1623-1630. Demonstration that reduced ghrelin secretion may contribute to weight loss after gastric bypass, as opposed to countering the effect of weight loss by dieting.
12. Ukkola O, Ravussin E, Jacobson P, et al.: Mutations in the preproghrelin gene associated with obesity in humans. J Clin Endocrinol Metab 2001, 86:3996-3999.
13. Cummings DE, Clement K, Purnell JQ, et al.: Elevated plasma ghrelin levels in Prader-Willi syndrome. Nature Med 2002, 8:643-644. Compares basal circulating ghrelin concentrations in lean persons, obese persons, and patients with Prader-Willi syndrome.
14. Geloneze B, Tambascia MA, Pilla VF: Ghrelin: a gut-brain hormone: effect of gastric bypass surgery. Obes Surg 2003, 13:17-22. Shows that gastric bypass reduces ghrelin levels in both diabetic and nondiabetic obese patients and also documents relationship with leptin.
15. Smart D, Jerman J: The physiology and pharmacology of the orexins. Pharmacol Ther 2002, 94:51-61. New review on the orexins.
16. Kirchgessner AL: Orexins in the brain-gut axis. Endocr Rev 2002, 23:1-15.
17. Ouedraogo R, Naslund E, Kirchgessner AL: Glucose regulates the release of orexin-A from the endocrine pancreas. Diabetes 2003, 52:111-117.
18. Zhu Y, Yamanaka A, Kunii K, et al.: Orexin-mediated feeding behavior involves both leptin-sensitive and -insensitive pathways. Physiol Behav 2002, 77:251-257. On the mechanisms of orexin-mediated effects on food intake.
19. Adam JA, Menheere PP, van Dielen FM, et al.: Decreased plasma orexin-A levels in obese individuals. Int J Obes Relat Metab Disord 2002, 26:274-276. Study of orexin levels in obesity.
20. Baranowska B, Radzikowska M, Wasileewska-Dziubinska E, et al.: Disturbed release of gastrointestinal peptides in anorexia nervosa and in obesity. Diabetes Obes Metab 2000, 2:99-103.
21. Naslund E, Gryback P, Hellstrom PM, et al.: Gastrointestinal hormones and gastric emptying 20 years after jejunoileal bypass for massive obesity. Int J Obes Relat Metab Disord 1997, 21:387-392.
22. Kellum JM, Kuemmerle JF, O'Dorisio TM, et al.: Gastrointestinal hormone responses to meals before and after gastric bypass and vertical banded gastroplasty. Ann Surg 1990, 211:763-770.
23. Takata Y, Takeda S, Kawanami T, et al.: Promoter analysis of human cholecystokinin type-A receptor gene. J Gastroenterol 2002, 37:815-820. Investigation of the importance of polymorphisms in the promoter region of the cholecystokinin gene on transcriptional control.
24. Reda TK, Geliebter A, Pi-Sunyer FX: Amylin, food intake, and obesity. Obes Res 2002, 10:1087-1091. Review of the role of amylin in control of food intake and body weight.
25. Arnelo U, Permert J, Larsson J, et al.: Chronic low dose islet amyloid polypeptide infusion reduces food intake but does not influence glucose metabolism in unrestrained conscious rats: studies using a novel aortic catheterization technique. Endocrinology 1997, 138:4081-4085.
26. Hayden MR: Islet amyloid, metabolic syndrome, and the natural progressive history of type 2 diabetes mellitus. J O Pancreas. 2002, 3:126-138.
27. Reidelberger RD, Arnelo U, Granqvist L, et al.: Comparative effects of amylin and cholecystokinin on food intake and gastric emptying in rats. Am J Physiol 2001, 280:R605-R611.
28. Morris MJ, Nguyen T: Does neuropeptide Y contribute to the anorectic action of amylin? Peptides 2001, 22:541-546.
29. Rushing PA, Hagan MM, Seeley RJ, et al.: Inhibition of central amylin signaling increases food intake and adiposity in rats. Endocrinology 2001, 142:5035-5038.
30. Holst JJ, Orskov C: Incretin hormones: an update. Scand J Clin Lab Invest Suppl 2001, 234:75-85.
31. Naslund E, Bogefors J, Skogar S, et al.: GLP-1 slows solid gastric emptying and inhibits insulin, glucagon and PYY release in humans. Am J Physiol 1999, 277:R910-R916.
32. Baron AD, Kim D, Weyer C: Novel peptides under development for the treatment of type 1 and type 2 diabetes mellitus. Curr Drug Targets Immune Endocr Metab Disord 2002, 2:63-82. Review of amylin and GLP-1 analogues being tested for clinical use.
33. Bloom SR, Polak JM: Gut hormones. Adv Clin Chem 1980, 21:177-244.
34. Sarson DL, Scopinaro N, Bloom SR: Gut hormone changes after jejunoileal (JIB) or biliopancreatic (BPB) bypass surgery for morbid obesity. Int J Obes 1981, 5:471-480.
35. Meryn S, Stein D, Straus EW: Pancreatic polypeptide, pancreatic glucagon and enteroglucagon in morbid obesity and following gastric bypass operation. Int J Obes 1986, 10:37-42.
36. Verdich C, Toubro S, Buemann B, et al.: The role of postprandial releases of insulin and incretin hormones in meal-induced satiety - effect of obesity and weight reduction. Int J Obes Relat Metab Disord 2001, 8:1206-1214.
37. Egan JM, Meneilly GS, Habener JF, et al.: Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state. J Clin Endocr Metab 2002, 87:3768-3773. Studies on the physiologic antidiabetic effects of GLP-1
38. Naslund E, Barkeling B, King N, et al.: Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord 1999, 3:304-311.
39. Flint A, Raban A, Ersboll AK, et al.: The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes Relat Metab Disord 2001, 6:781-792.
40. Larsen PJ, Fledelius C, Knudsen LB, et al.: Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss n both normal and obese rats. Diabetes 2001, 11:2530-2539.
41. Shalev A, Holst JJ, Keller U: Effects of glucagon-like peptide-1 (7-36 amide) on whole-body protein metabolism in healthy man. Eur J Clin Invest 1997, 27:10-16.
42. Alcantara AI, Morales M, Delgado E, et al.: Exendin-4 and exendin(9-39)amide antagonist of the GLP-1(7-36)amide effects in liver and muscle. Arch Biochem Biophys 1997, 341:1-7.
43. Luque MA, Gonzalez N, Marquez L: Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes. J Endocrinol 2002, 173:465-473. Studies on the mechanisms of the direct effects of GLP-1 on skeletal muscle glucose metabolism.
44. Meier JJ, Gallwitz B, Schmidt WE, et al.: Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives. Eur J Pharmacol 2000, 440:269-279.
45. Tatemoto K, Mutt V: Isolation of two novel candidate hormones using a chemical method for finding naturally occurring polypeptides. Nature 1980, 285:417-418.
46. Adrian TE, Ferri G-L, Bacarese-Hamilton AJ, et al.: Human distribution and release of a putative new gut hormone, peptide YY (PYY). Gastroenterology 1985, 89:1070-1077.
47. Savage AP, Adrian TE, Carolan G, et al.: Effects of peptide YY (PYY) on mouth to cecum intestinal transit time and on the rate of gastric emptying in healthy volunteers. Gut 1987, 70:166-170.
48. Adrian TE, Savage AP, Sagor GR, et al.: Effect of PYY on gastric pancreatic and biliary function in man. Gastroenterology 1985, 89:494-499.
49. Bilchik AJ, Hines OJ, Adrian TE, et al.: Peptide YY is a physiological regulator of water and electrolyte absorption in the canine small bowel in vivo. Gastroenterology 1993, 105:1441-1448.
50. Batterham RL, Cowley MA, Small CJ: Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002, 418:650-654. First demonstration of the inhibitory effects of truncated PYY on food intake in humans and other species and the mechanisms involved.
51. Adrian TE, Savage AP, Bacarese-Hamilton MJ, et al.: Peptide YY abnormalities in gastrointestinal disease. Gastroenterology 1986, 90:379-384.
52. Adrian TE, Savage AP, Fuessl HS, et al.: Release of peptide YY (PYY) after resection of small bowel, colon or pancreas in man. Surgery 1987, 101:715-719.
53. Alvarez Bartolome M, Borque M, Martinez-Sarmiento J, et al.: Peptide YY secretion in morbidly obese patients before and after vertical banded gastroplasty. Obes Surg 2002, 12:324-327. Studies on the secretion of PYY in obesity and after bariatric surgery.
54. Adrian TE, Thompson JS, Quigley EM: Time-course of adaptive regulatory peptide changes following massive small bowel resection in the dog. Dig Dis Sci 1996, 41:1194-1203.
55. Weiss H, Labeck B, Klocker J, et al.: Effects of adjustable gastric banding on altered gut neuropeptide levels in morbidly obese patients. Obes Surg 2001, 11:735-739.
56. Miskowiak J, Pedersen JH, Andersen B, et al.: Plasma levels of neurotensin in gastroplasty for morbid obesity. Regul Pept 1984, 9:263-269.
57. Van Dielen FMH, Van 'T Veer C, Buurman WA, et al.: Leptin and soluble leptin receptor levels in obese and weight-losing individuals. J Clin Endocrinol Metab 2002, 87:1708-1716. Influence of weight loss due to bariatric surgery or dieting on circulating leptin concentrations.
58. Bado A, Levasseur S, Attoub S, et al.: The stomach is a source of leptin. Nature 1998, 394:790-793.
59. Attele AS, Shi ZQ, Yuan C-S: Leptin, gut, and food intake. Biochem Pharm 2002, 63:1579-1583.
60. Anini Y, Brubaker PL. Role of leptin in the regulation of glucagon-like peptide-1 secretion. Diabetes 2003; 52: 252-259.
61. Geloneze B, Tambascia MA, Pareja JC, et al.: Serum leptin levels after bariatric surgery across a range of glucose tolerance from normal to diabetes. Obes Surg 2001, 11:693-698.
62. De Marinis L, Mancini A, Valle D, et al.: Plasma leptin levels after biliopancreatic diversion: dissociation with body mass index. J Clin Endocrinol Metab 1999, 84:2386-2389.
63. Mason EE: Ileal transposition and enteroglucagon/GLP-1 in obesity (and diabetic?) surgery. Obes Surg 1999, 9:223-228.